Search

Your search keyword '"Kamal, Mehta Vedant"' showing total 8 results
Start Over Author "Kamal, Mehta Vedant"
8 results on '"Kamal, Mehta Vedant"'

6. In Vitro Cytotoxic Activity and In Vivo Antiproliferative Activity of Ethyl Acetate Fraction of Bunium bulbocastanumSeed Against Prostatic Neoplasia

Author

Kamal, Mehta Vedant, Pai, Sreedhara Ranganath K., Hari, Gangadhar, Priya, Keerthi, Godkhindi, Vishwapriya Mahadev, Pai, Ananth, Dikhit, Punit Singh, and Belle, Vijetha Shenoy

Abstract

Several in vitro investigations of the therapeutic characteristics of B. bulbocastanumhave shown that it has cytotoxic, antifungal, and antibacterial effects. It also exhibits antioxidant and anticancer effects. When the ethyl acetate fraction of B. bulbocastanumwas examined for its phytochemical composition, it was found to be rich in phenolic compounds and had significant cytotoxic effects on PC-3 cell lines. The prostate length-to-weight ratio was significantly higher in vivo in the ethyl acetate fraction-treated group. Compared to the disease control group, histopathological examination of the ethyl acetate-treated group revealed a reduction in inflammation and malignant lesions, confirming its antiproliferative efficacy. According to serum biochemistry, acid phosphatase and PSA levels in the ethyl acetate fraction treatment group were significantly lower than those in the disease control group. When compared to the disease control group, malondialdehyde levels in the ethyl acetate fraction treatment group were likewise reduced dramatically. However, in the group treated with the ethyl acetate fraction, glutathione levels increased considerably. The ethyl acetate fraction of B. bulbocastanummay have cytotoxic and antiproliferative potential, both in vitro and in vivo.

Published
2024
Full Text
View/download PDF

8. A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma.

Author

Kamal, Mehta Vedant, Rao, Mahadev, Damerla, Rama Rao, Pai, Ananth, Sharan, Krishan, Palod, Akhil, Shetty, Preethi S., Usman, Nawaz, and Kumar, Naveena A.N.

Subjects
*CYCLOOXYGENASE 2, *IN vitro studies, *MOUTH tumors, *IN vivo studies, *NONSTEROIDAL anti-inflammatory agents, *NEOVASCULARIZATION, *HEAD & neck cancer, *METHOTREXATE, *IMMUNITY, *SQUAMOUS cell carcinoma, *PALLIATIVE treatment
Abstract

The combination of low-dose methotrexate and celecoxib as metronomic chemotherapy (MCT) is a novel therapy, believed to act by modulating the immune response, inhibiting angiogenesis and its cytotoxic action, though the exact mechanism of action is unclear. Clinically, MCT was found to be very effective in delaying tumor progression in patients with head and neck squamous cell carcinoma in both curative and palliative settings. This review was aimed to give a brief insight into the mechanism of action and potential molecular alterations of MCT in the treatment of oral cancers taking into consideration the various in vivo and in vitro studies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results